IL285084A - Inositol phosphate compounds for use in increasing tissular perfusion - Google Patents

Inositol phosphate compounds for use in increasing tissular perfusion

Info

Publication number
IL285084A
IL285084A IL285084A IL28508421A IL285084A IL 285084 A IL285084 A IL 285084A IL 285084 A IL285084 A IL 285084A IL 28508421 A IL28508421 A IL 28508421A IL 285084 A IL285084 A IL 285084A
Authority
IL
Israel
Prior art keywords
phosphate compounds
inositol phosphate
tissue perfusion
increasing tissue
increasing
Prior art date
Application number
IL285084A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of IL285084A publication Critical patent/IL285084A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL285084A 2019-01-30 2021-07-22 Inositol phosphate compounds for use in increasing tissular perfusion IL285084A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
US201962913259P 2019-10-10 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
IL285084A true IL285084A (en) 2021-09-30

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285084A IL285084A (en) 2019-01-30 2021-07-22 Inositol phosphate compounds for use in increasing tissular perfusion

Country Status (11)

Country Link
US (2) US20220000889A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917535A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022521119A (cg-RX-API-DMAC7.html)
KR (1) KR20210148078A (cg-RX-API-DMAC7.html)
CN (1) CN113365636A (cg-RX-API-DMAC7.html)
AU (1) AU2020213713B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014897A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130735A1 (cg-RX-API-DMAC7.html)
IL (1) IL285084A (cg-RX-API-DMAC7.html)
MX (1) MX2021008966A (cg-RX-API-DMAC7.html)
WO (1) WO2020157362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003653A (es) 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
AU2021380963A1 (en) * 2020-11-20 2023-06-22 ETH Zürich Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
AU6912500A (en) * 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
MX347723B (es) 2011-09-29 2017-05-10 Eth Zuerich Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
ES2762984T3 (es) 2015-12-11 2020-05-26 Eth Zuerich 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile
SMT202100406T1 (it) * 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica

Also Published As

Publication number Publication date
KR20210148078A (ko) 2021-12-07
EP3917535A1 (en) 2021-12-08
JP2024175025A (ja) 2024-12-17
US20220000889A1 (en) 2022-01-06
AU2020213713A1 (en) 2021-07-22
MX2021008966A (es) 2021-11-04
BR112021014897A2 (pt) 2021-09-28
WO2020157362A1 (en) 2020-08-06
CN113365636A (zh) 2021-09-07
JP2022521119A (ja) 2022-04-06
AU2020213713B2 (en) 2025-08-21
CA3130735A1 (en) 2020-08-06
US20230248749A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
EP3989793C0 (en) SURGICAL CONSOLE INTERFACE
EP3541287A4 (en) RADIOTHERAPY PATIENT PLATFORM
EP3322361A4 (en) BONE POSITIONING LEADERSHIP
EP2814397A4 (en) SYSTEM FOR TESTING THE EFFECTS OF ABLATION THERAPY ON HEART TISSUE BY PHOTOACOUSTICS
EP3813693C0 (en) MEDICAL INSTRUMENT FOR PERCUTANEOUS RELEASE PROCEDURES
EP4035608C0 (en) Medical instrument
MX2020003049A (es) Semaglutida en la terapia medica.
EP3399515A4 (en) MEDICAL SIMULATOR FOR SIMULATION OF PUNCTION PROCESSES
LT3609886T (lt) Benzoazepino analogai kaip brutono tirozinkinazės inhibitoriai
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
PL3768284T3 (pl) Kompozycje z fageliny entrecoccus do zastosowania w terapii
EP3834750C0 (en) MEDICAL INSTRUMENT
DK3151851T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
EP3681539C0 (en) COMPLEX IRON COMPOUNDS FOR THERAPEUTIC USE
EP3708131C0 (en) CIRCULATION LINE FOR INTRACAVITICAL HYPERTHERMIC PERFUSION
PL3685781T3 (pl) Przyrząd do koagulacji tkanek
DK3465214T3 (da) Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EP3747479A4 (en) MEDICAL INSTRUMENT
IL280638A (en) Adipose tissue treatment
JP2020523063A5 (ja) 血液成分採取用カセット
EP4026572A4 (en) MEDICAL INSTRUMENT
EP3302223A4 (en) MEDICAL OPTICAL EXAMINATION INSTRUMENT
EP3887514A4 (en) THERAPEUTIC GENERATE EDITING FOR ELAN-ASSOCIATED DISEASE
EP3834747A4 (en) MEDICAL INSTRUMENT